Search for: "Lupin Pharmaceuticals"
Results 141 - 160
of 175
Sort by Relevance
|
Sort by Date
13 Mar 2009, 2:00 am
(Patent Baristas) US: Schering merger includes legal headaches for Merck, including IP suits (Law360) US: Lessig and Eisen article ‘Is John Conyers Shilling for Special Interests’ concerning proposal to ban open access publishing requirement for taxpayer funded medical scientists (Huffington Post) (Lessig) (Lenz Blog) (Lessig) (Lenz Blog) (Michigan Messenger) (Lessig) US: McCain touts drug imports to lower US costs (Law360) US: Biotech and pharma provide little support in… [read post]
9 Feb 2009, 11:32 pm
(alleged infringers)Eli Lilly's (patent owner) Cymbalta drugAstraZeneca's (patent owner) Crestor drugPenwest Pharmaceuticals (patent owner) Opana ER drugSepracor's (patent owner) Xyzal drugOf Apple and US 7,479,949, see the IPBiz post Obvious? [read post]
23 Jan 2009, 12:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: India: Discussion of Delhi High Court Dasatinib order – patent linkage between Indian Patent Office and Office of the Drug Controller General of India (Patent Circle) (Spicy IP) (Patent Circle) (Managing Intellectual Property) Lescol (Fluvastatin) – US: EWHC finds sustained release Fluvastatin patent invalid on ground of… [read post]
22 Jan 2009, 11:57 pm
Lupin Ltd. et alOscient Pharmaceuticals Corporation, holder of the NDA license for anti-cholesterol drug Antara (generically Fenofibrate) jointly with Guardian II Acquisition Corporation and Ethypharm has filed a civil action for patent infringement against Pune-based Lupin Ltd. for infringement of Orange-Book listed US Patent No. 7,101,574 ("Pharmaceutical composition containing fenofibrate and the preparation method"). [read post]
18 Jan 2009, 7:28 pm
Lupin Ltd. et al.1:09-cv-00083; filed January 14, 2009 in the District Court of MarylandInfringement of U.S. [read post]
16 Jan 2009, 5:00 am
(IP finance) US: Medarex, Eurand and Alexion file actions against Director Dudas seeking revised patent term adjustment determinations (Patent Docs) US: Kubin panel questions motivation behind reversal in new Written Description Training Materials (Patent Docs) US: The obviousness of DNA - Federal Circuit heard oral argument for In re Kubin last week (Patent Docs) Products Antara (Fenofibrate) – US: Oscient and Ethypharm file patent infringement suit against Lupin over… [read post]
28 Dec 2008, 2:24 pm
Lupin Pharmaceuticals, Inc. et al.3:08-cv-06261;... [read post]
24 Dec 2008, 9:04 am
After Lupin, Dr. [read post]
19 Dec 2008, 1:00 pm
$16.8 million for Alphapharm and Mylan: Takeda v Mylan (Patent Baristas) (Patent Docs) Boniva (Ibandronic acid) – US: Apotex challenges validity of Hoffmann-La Roche’s Boniva patent (Law360) Boniva (Ibandronic acid) – US: Orchid Chemicals & Pharmaceuticals and Orgenus Pharma seek declaratory judgment of invalidity and noninfringement in patent infringement suit brought by Hoffmann-La Roche over Boniva (Law360) Cardizem (Diltiazem) – Antitrust,… [read post]
16 Dec 2008, 11:47 pm
Lupin, Ltd. 499 F.3d 1293, 1302 (Fed. [read post]
5 Dec 2008, 1:00 pm
(Holman's Biotech IP Blog) IP and genetically modified organisms: a fateful combination, activists say (Intellectual Property Watch) Australia: Gene patent delays diagnosis and treatment for babies with severe form of epilepsy: (Techdirt) Brazil: Brazilian draft law would curb expanded patents on pharmaceuticals (Intellectual Property Watch) (IP tango) EU: European Commission issues preliminary report on its inquiry into competition in the pharmaceutical sector (IPKat)… [read post]
28 Nov 2008, 12:49 pm
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: EPO Enlarged Board of Appeal turns down Wisconsin Alumni Research Foundation (WARF) stem cell application (IAM) (IPKat) (EPO) European Commission releases… [read post]
8 Sep 2008, 4:36 am
Teva Pharmaceutical... [read post]
25 Jul 2008, 2:11 am
Lupin, Ltd., 499 F.3d 1293, 1301 (Fed. [read post]
26 Jun 2008, 3:39 am
We reported last month that King Pharmaceuticals filed a citizen petition that could delay final approval of numerous ANDAs for generic versions of Altace (ramipril), which were set to earn final approval on June 7. [read post]
16 Jun 2008, 10:00 am
I've previously blogged about Lupin's successful development, patenting and sale of its Coversyl IP porfolio to Servier (see Pharmaceutical Lifecycle Management & IP acquisitions). [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real story:… [read post]
9 Jun 2008, 4:50 am
Lupin Limited et al. v. [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay generics in 2007:… [read post]
26 May 2008, 9:11 pm
King Pharmaceuticals markets Altace (ramipril), which is indicated for the treatment of high blood pressure. [read post]
